Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)
Brief Summary: This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents. This protocol is intended to evaluate various drug combinations with JCAR017, as separate arms, over the life of the protocol, using the same objectives. Each combination will be evaluated separately (ie, the intention is not to compare between combinations) for the purposes of the objectives, trial design, and statistical analysis. The following combinations will be tested:

Arm A: JCAR017 in combination with durvalumab Arm B: JCAR017 in combination with CC-122 (avadomide) Arm C: JCAR017 in combination with CC-220 (iberdomide) Arm D: JCAR017 in combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and/or nivolumab Arm F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment once combination agents have been selected.

The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.


Options:
A: Arm Label: WZTL002-1 (1928T2z CAR T-cells); Type: EXPERIMENTAL; Interventions: Biological: WZTL002-1 (1928T2z CAR-T cells), Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy | Intervention Type: BIOLOGICAL; Name: WZTL002-1 (1928T2z CAR-T cells); Assigned to Arm(s): WZTL002-1 (1928T2z CAR T-cells) | Intervention Type: DRUG; Name: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy; Assigned to Arm(s): WZTL002-1 (1928T2z CAR T-cells)
B: Arm Label: Arm A: JCAR017 in combination with Durvalumab; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Durvalumab | Arm Label: Arm B: JCAR017 in combination with CC-122; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-122 | Arm Label: Arm C: JCAR017 in combination with CC-220; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-220 | Arm Label: Arm D: JCAR017 in combination with Ibrutinib; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Ibrutinib | Arm Label: Arm E: JCAR017 in combination with relatlimab and/or nivolumab; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: Relatlimab, Drug: Nivolumab | Arm Label: Arm F: JCAR017 in combination with CC-99282; Type: EXPERIMENTAL; Interventions: Biological: JCAR017, Drug: CC-99282 | Intervention Type: BIOLOGICAL; Name: JCAR017; Assigned to Arm(s): Arm A: JCAR017 in combination with Durvalumab, Arm B: JCAR017 in combination with CC-122, Arm C: JCAR017 in combination with CC-220, Arm D: JCAR017 in combination with Ibrutinib, Arm E: JCAR017 in combination with relatlimab and/or nivolumab, Arm F: JCAR017 in combination with CC-99282 | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Arm A: JCAR017 in combination with Durvalumab | Intervention Type: DRUG; Name: CC-122; Assigned to Arm(s): Arm B: JCAR017 in combination with CC-122 | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm D: JCAR017 in combination with Ibrutinib | Intervention Type: DRUG; Name: CC-220; Assigned to Arm(s): Arm C: JCAR017 in combination with CC-220 | Intervention Type: DRUG; Name: Relatlimab; Assigned to Arm(s): Arm E: JCAR017 in combination with relatlimab and/or nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm E: JCAR017 in combination with relatlimab and/or nivolumab | Intervention Type: DRUG; Name: CC-99282; Assigned to Arm(s): Arm F: JCAR017 in combination with CC-99282
C: Arm Label: ACTR087, in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR087, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR087; Assigned to Arm(s): ACTR087, in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR087, in combination with rituximab
D: Arm Label: Treatment Regimen; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: anti-CD19 CAR-T cells | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Treatment Regimen | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment Regimen | Intervention Type: BIOLOGICAL; Name: anti-CD19 CAR-T cells; Assigned to Arm(s): Treatment Regimen

Answer: B